

PRODUCT

Mary Metre as the section affirmet a could metre the section of th

Fecal excretion of the unabsorbed drug is the major route of

elimination (approximately 97%). Orlistat and its M1 and M3

R&D

RND

Colour Key Black Learlet: Flying Paper 55 gm **Si** ze W 90 H: 14

Distribution: erythrocytes. Metabolism:

TrimZak is a lipase inhibitor for obesity management that acts by inhibiting the absorption of detary fats.

CLINICAL PHARMACOLOGY:

Mode of action:

Orlistat is a reversible inhibitor of lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monodycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control. Systemic absorption of the drug is therefore not needed for activity. At the recommended therapeutic dose of 120 mg three times a day;

Orlistat inhibits dietary fat absorption by approximately 30 %. Pharmacokinetics:

Systemic exposure to Orlistat is minimal. Following oral dosing with 360 mg Orlistat, plasma concentrations of intact drug were near the limits of detection (<5 ng/mL). In therapeutic studies involving monitoring of plasma samples, detection of intact Orlistat in plasma was sporadic and concentrations were low (<10 ng/ml), without evidence of accumulation and consistent with minimal absorption.

Orlistat was >99% bound to plasma proteins (lipoproteins and albumin are major

binding proteins). Orlistat minimally partitioned into

Metabolism of Orlistat occurs mainly within the gastrointestinal wall. Two metabolites, M1 (4-member lactone ring hydrolyzed) and M3 (M1 with N-formy/leucine moiety deaved) accounted for approximately 42% of total radioactivity in plasma. M1 and M3 have an open G-lactone ring and extremely weak lipase inhibitory activity (1000- and 2500-fold less than Oristat respectively). In view of this low inhibitory activity and the low plasma levels at therapeutic dose, these metabolites are considered pharmacologically inconsequential. The primary metabolite M1 has a short half-life (approximately3 hours) whereas the secondary metabolite M3 disappeared at a slower rate (half-life approximately 13.5 hours).

Fecal excretion of the unabsorbed drug is the major route of elimination (approximately 97%). Orlistat and its M1 and M3 metabolites are also subjected to biliary excretion. The time to

PAG

TrimZak is a lipase inhibitor for obesity management that acts by inhibiting the absorption of detary fats.

CLINICAL PHARMACOLOGY:

Mode of action:

Orlistat is a reversible inhibitor of lipases. It exerts its therapeutic activity in the lumen of the stomach and small intestine by forming a covalent bond with the active serine residue site of gastric and pancreatic lipases. The inactivated enzymes are thus unavailable to hydrolyze dietary fat in the form of triglycerides into absorbable free fatty acids and monoglycerides. As undigested triglycerides are not absorbed, the resulting caloric deficit may have a positive effect on weight control. Systemic absorption of the drug is therefore not needed for activity. At the recommended therapeutic dose of 120 mg three times a day,

Orlistat inhibits dietary fat absorption by approximately 30 %. Pharmacokinetics:

Absorption:

Systemic exposure to Orlistat is minimal. Following oral dosing with 360 mg Orlistat, plasma concentrations of intact drug were near the limits of detection (<5 ng/mL). In therapeutic studies involving monitoring of plasma samples, detection of intact Orlistat in plasma was sporadic and concentrations were low (<10 ng/ml), without evidence of accumulation and consistent with minimal absorption.

Distribution:

Orlistat was >99% bound to plasma proteins (lipoproteins and albumin are major


binding proteins). Orlistat minimally partitioned into erythrocytes.

Metabolism:

Metabolism of Orlistat occurs mainly within the gastrointestinal wall. Two metabolites, M1 (4-member lactone ring hydrolyzed) and M3 (M1 with N-formy) leucine moiety deaved) accounted for approximately 42% of total radioactivity in plasma. M1 and M3 have an open & lactone ring and extremely weak lipase inhibitory activity (1000- and 2500-fold less than Orlistat respectively). In view of this low inhibitory activity and the low plasma levels at therapeutic dose, these metabolites are considered pharmacologically inconsequential. The primary metabolite M1 has a short half-life (approximately3 hours) whereas the secondary metabolite M3 disappeared at a slower rate (half-life approximately 13.5 hours).

Fecal excretion of the unabsorbed drug is the major route of

elimination (approximately 97%). Orlistat and its M1 and M3 metabolites are also subjected to biliary excretion. The time to correspondence complete excretion (fecal plus urinary) is 3 to 5 days.



Chesitymanagergent including weight loss and weight maintenance whenever

- used in conjunction with a reduced calorie diet.
- Obese patients with an initial body mass index (BMI) >30
- maintenance when used in conjunction with a reduced calorie diet.
- Obese patients with an initial body mass index (BMI) >30

Colour Key Beatlet: Flying Paper 55 gm